-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Helus Pharma, Raises Price Target to $49

Benzinga·11/19/2026 14:06:32
Listen to the news
Guggenheim analyst Eddie Hickman maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $45 to $49.